JP2013544866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544866A5 JP2013544866A5 JP2013542537A JP2013542537A JP2013544866A5 JP 2013544866 A5 JP2013544866 A5 JP 2013544866A5 JP 2013542537 A JP2013542537 A JP 2013542537A JP 2013542537 A JP2013542537 A JP 2013542537A JP 2013544866 A5 JP2013544866 A5 JP 2013544866A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hetaryl
- aryl
- cycloalkyl
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- -1 Carboxamide compounds Chemical class 0.000 claims 54
- 125000001072 heteroaryl group Chemical group 0.000 claims 30
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000001424 substituent group Chemical group 0.000 claims 21
- 238000011282 treatment Methods 0.000 claims 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000006771 (C1-C6) haloalkylthio group Chemical group 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- UQLATLVPRRMUST-UHFFFAOYSA-N 2-(5-fluoroindazol-2-yl)-n-[4-(methoxyamino)-3,4-dioxo-1-phenylbutan-2-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=C(N2N=C3C=CC(F)=CC3=C2)C=1C(=O)NC(C(=O)C(=O)NOC)CC1=CC=CC=C1 UQLATLVPRRMUST-UHFFFAOYSA-N 0.000 claims 1
- QQPUPOYIRHLEPY-UHFFFAOYSA-N 2-(6-fluoroindazol-2-yl)-n-[4-(methoxyamino)-3,4-dioxo-1-phenylbutan-2-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=C(N2N=C3C=C(F)C=CC3=C2)C=1C(=O)NC(C(=O)C(=O)NOC)CC1=CC=CC=C1 QQPUPOYIRHLEPY-UHFFFAOYSA-N 0.000 claims 1
- WASRBFBECXBKPU-UHFFFAOYSA-N 2-indazol-2-yl-n-[4-(methoxyamino)-3,4-dioxo-1-phenylbutan-2-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=C(N2N=C3C=CC=CC3=C2)C=1C(=O)NC(C(=O)C(=O)NOC)CC1=CC=CC=C1 WASRBFBECXBKPU-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 1
- 102000007590 Calpain Human genes 0.000 claims 1
- 108010032088 Calpain Proteins 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000013875 Heart injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000029549 Muscle injury Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- JAJXQKSUOMEQIL-UHFFFAOYSA-N n-[4-(cyclopropylamino)-3,4-dioxo-1-phenylbutan-2-yl]-2-indazol-2-ylpyridine-3-carboxamide Chemical compound C=1C=CC=CC=1CC(NC(=O)C=1C(=NC=CC=1)N1N=C2C=CC=CC2=C1)C(=O)C(=O)NC1CC1 JAJXQKSUOMEQIL-UHFFFAOYSA-N 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000028172 protozoa infectious disease Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42132310P | 2010-12-09 | 2010-12-09 | |
| US61/421,323 | 2010-12-09 | ||
| PCT/EP2011/072164 WO2012076639A1 (en) | 2010-12-09 | 2011-12-08 | Carboxamide compounds and their use as calpain inhibitors v |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013544866A JP2013544866A (ja) | 2013-12-19 |
| JP2013544866A5 true JP2013544866A5 (enExample) | 2015-01-22 |
Family
ID=45349178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542537A Ceased JP2013544866A (ja) | 2010-12-09 | 2011-12-08 | カルボキサミド化合物及びカルパイン阻害剤ｖとしてのその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9062027B2 (enExample) |
| EP (1) | EP2648731B1 (enExample) |
| JP (1) | JP2013544866A (enExample) |
| CN (1) | CN103501784A (enExample) |
| CA (1) | CA2819087A1 (enExample) |
| MX (1) | MX2013006419A (enExample) |
| WO (1) | WO2012076639A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015173133A1 (en) | 2014-05-12 | 2015-11-19 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| EP3426674A4 (en) | 2016-03-09 | 2019-08-14 | Blade Therapeutics, Inc. | CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US11292801B2 (en) | 2016-07-05 | 2022-04-05 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
| AU2017336523B2 (en) | 2016-09-28 | 2022-07-21 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
| BR112020019325A2 (pt) * | 2018-03-28 | 2021-01-05 | Blade Therapeutics, Inc. | Método de tratamento de doença fibrótica |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826835A (en) | 1985-10-23 | 1989-05-02 | Rorer Pharmaceutical Corporation | Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure |
| US4743608A (en) | 1986-07-15 | 1988-05-10 | Rorer Pharmaceutical Corporation | Pyridone-pyridyl-imidazolyl and triazolyl compounds and their use as cardiotonic agents |
| DE19642591A1 (de) | 1996-10-15 | 1998-04-16 | Basf Ag | Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung |
| DE19650975A1 (de) | 1996-12-09 | 1998-06-10 | Basf Ag | Neue heterocyclisch substituierte Benzamide und deren Anwendung |
| PL334059A1 (en) | 1996-12-11 | 2000-01-31 | Basf Ag | Ketone benzamides useful as calpain inhibitors |
| US6083944A (en) | 1997-10-07 | 2000-07-04 | Cephalon, Inc. | Quinoline-containing α-ketoamide cysteine and serine protease inhibitors |
| DE19817459A1 (de) | 1998-04-20 | 1999-10-21 | Basf Ag | Neue heterozyklische substituierte Amide, Herstellung und Anwendung |
| CA2328396C (en) | 1998-04-20 | 2009-02-10 | Basf Aktiengesellschaft | New substituted amides, their production and their use |
| BR9909819A (pt) | 1998-04-20 | 2000-12-19 | Basf Ag | Amida, uso de amidas, e, preparação farmacêutica para uso oral, parenteral ou intraperitoneal |
| DE19818614A1 (de) | 1998-04-20 | 1999-10-21 | Basf Ag | Neue substituierte Amide, deren Herstellung und Anwendung |
| ES2325140T3 (es) | 1998-04-20 | 2009-08-26 | ABBOTT GMBH & CO. KG | Amidas sustituidas con heterociclos como inhibidores de la calpaina. |
| WO1999061423A1 (de) | 1998-05-25 | 1999-12-02 | Basf Aktiengesellschaft | Neue heterocyclische substituierte amide, deren herstellung und anwendung |
| DE10114762A1 (de) | 2001-03-26 | 2002-10-02 | Knoll Gmbh | Verwendung von Cysteinprotease-Inhibitoren |
| US20070105781A1 (en) | 2005-08-02 | 2007-05-10 | Steve Lyons | Inhibitors of serine proteases |
| CN101616908B (zh) * | 2006-12-29 | 2014-09-10 | Abbvie德国有限责任两合公司 | 羧酰胺化合物及它们作为钙蛋白酶抑制剂的用途 |
| CA2679377A1 (en) | 2007-02-26 | 2008-09-04 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of hcv replication |
| TWI453019B (zh) * | 2007-12-28 | 2014-09-21 | Abbvie Deutschland | 甲醯胺化合物 |
| TWI519530B (zh) * | 2009-02-20 | 2016-02-01 | 艾伯維德國有限及兩合公司 | 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途 |
| US9051304B2 (en) * | 2009-12-22 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Carboxamide compounds and their use as calpain inhibitors V |
| US8598211B2 (en) * | 2009-12-22 | 2013-12-03 | Abbvie Inc. | Carboxamide compounds and their use as calpain inhibitors IV |
-
2011
- 2011-12-08 EP EP11796664.8A patent/EP2648731B1/en not_active Not-in-force
- 2011-12-08 WO PCT/EP2011/072164 patent/WO2012076639A1/en not_active Ceased
- 2011-12-08 MX MX2013006419A patent/MX2013006419A/es not_active Application Discontinuation
- 2011-12-08 CA CA2819087A patent/CA2819087A1/en not_active Abandoned
- 2011-12-08 CN CN201180067241.2A patent/CN103501784A/zh active Pending
- 2011-12-08 US US13/992,582 patent/US9062027B2/en not_active Expired - Fee Related
- 2011-12-08 JP JP2013542537A patent/JP2013544866A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013515040A5 (enExample) | ||
| JP2014514360A5 (enExample) | ||
| JP2012526082A5 (enExample) | ||
| RU2013104459A (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов | |
| JP2014520898A5 (enExample) | ||
| JP2013533879A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2013544866A5 (enExample) | ||
| JP2013505930A5 (enExample) | ||
| RU2350616C2 (ru) | Производные пиразоло- и имидазопиримидина | |
| JP2007505933A5 (enExample) | ||
| JP2012507566A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| JP2013502431A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2013544860A5 (enExample) | ||
| JP2013509431A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2007534695A5 (enExample) | ||
| JP2013508288A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2015517566A5 (enExample) | ||
| JP2009529047A5 (enExample) | ||
| JP2014513140A5 (enExample) | ||
| JP2009513703A5 (enExample) |